VANCOUVER, British Columbia -- Treatment with higher-exposure dupilumab (Dupixent) led to sustained improvements in the reduction of peak esophageal intraepithelial eosinophil counts among children ...

Please provide your email address to receive an email when new articles are posted on . Revolo Biotherapeutics’ ‘1104 is designed to reset the immune system “upstream” before the inflammatory cascade ...

PHOENIX -- Nearly three-fifths of patients with eosinophilic esophagitis (EoE) achieved remission after treatment with dupilumab (Dupixent), researchers reported. In a 6-month study, 58.8% of adults ...

Findings showed a greater proportion of patients treated with dupilumab met the primary endpoint achieving histological disease remission. The Food and Drug Administration (FDA) has expanded the ...

Benralizumab is an eosinophil-depleting anti–interleukin-5 receptor α monoclonal antibody. The efficacy and safety of benralizumab in patients with eosinophilic esophagitis are unclear. In a phase 3, ...

Credit: Medical Images. A PDUFA target date of January 31, 2024 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

The phase 3 EoE KIDS study included 102 children with active eosinophilic esophagitis based on histologic improvement meeting validated histologic criteria. Positive results were announced from a ...

Please provide your email address to receive an email when new articles are posted on . Researchers identified treatment disparities between incarcerated people with asthma and other chronic health ...

Results showed higher-exposure dupilumab met the study’s primary endpoint for peak esophageal intraepithelial count ≤6 eos/high-power field. Dupilumab may be a safe and effective treatment for ...

Sanofi and Regeneron Thursday announced positive results from a pivotal phase 3 trial of dupilumab (Dupixent) in children aged 1 to 11 years who have eosinophilic esophagitis (EoE). Dupilumab was ...

HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company’s ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE).

Study met primary endpoint demonstrating barzolvolimab’s ability to potently deplete mast cells in the gastrointestinal tract Profound mast cell depletion did not result in improved clinical outcomes ...